It's convinced the 2nd gen Transformer model is good enough that you will.

What began as a stack of fragile, century-old mine maps is being transformed into an immersive 3D window into the past by ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

We may earn a commission from links on this page. Deal pricing and availability subject to change after time of publication. Black Friday sales officially start Friday, November 28, and run through ...

Getting in on the ground floor would be great, but only if there's massive upside ahead for the company. Several stocks on the market offer investors the opportunity to capitalize on the rapidly ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Revolutionary Impact: Imagine your code being visualized in real-time as interactive digital artwork, reflecting its structure, logic flow, and even emotional context. Every piece of code you write ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

In AI research, progress is often equated with size. But a small team at Samsung’s AI lab in Montreal has taken another approach that is proving to show great promise. Their new Tiny Recursive Model ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...